A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients

Journal of Translational Medicine
Susana InogésRicardo Díez Valle

Abstract

Prognosis of patients with glioblastoma multiforme (GBM) remains dismal, with median overall survival (OS) of about 15 months. It is therefore crucial to search alternative strategies that improve these results obtained with conventional treatments. In this context, immunotherapy seems to be a promising therapeutic option. We hypothesized that the addition of tumor lysate-pulsed autologous dendritic cells (DCs) vaccination to maximal safe resection followed by radiotherapy and concomitant and adjuvant temozolomide could improve patients' survival. We conducted a phase-II clinical trial of autologous DCs vaccination in patients with newly diagnosed patients GBM who were candidates to complete or near complete resection. Candidates were finally included if residual tumor volume was lower than 1 cc on postoperative radiological examination. Autologous DCs were generated from peripheral blood monocytes and pulsed with autologous whole tumor lysate. The vaccination calendar started before radiotherapy and was continued during adjuvant chemotherapy. Progression free survival (PFS) and OS were analyzed with the Kaplan-Meier method. Immune response were assessed in blood samples obtained before each vaccines. Thirty-two consecutive pat...Continue Reading

References

Jul 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D R MacdonaldJ G Cairncross
Aug 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christopher J WheelerKeith L Black
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Jun 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ryuya YamanakaRyuichi Tanaka
Aug 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Linda M LiauMichael D Roth
Jul 10, 2007·Acta Neuropathologica·David N LouisPaul Kleihues
Apr 22, 2008·Neurosurgery·Walter StummerUNKNOWN ALA-Glioma Study Group
May 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Steven De VleeschouwerStefaan W Van Gool
May 23, 2008·Neurosurgery·Nader Sanai, Mitchel S Berger
Jun 21, 2008·The New England Journal of Medicine·Olivera J Finn
Oct 5, 2010·International Journal of Radiation Oncology, Biology, Physics·Jing LiMinesh P Mehta
Oct 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John H SampsonDarell D Bigner
Dec 8, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert M PrinsLinda M Liau
Mar 23, 2011·Journal of Neurosurgery·Nader SanaiMitchel S Berger
May 24, 2011·Clinical Medicine Insights. Oncology·Marc C Chamberlain
Mar 23, 2012·Nature Reviews. Cancer·Karolina Palucka, Jacques Banchereau
Aug 1, 2012·Cancer Immunology, Immunotherapy : CII·Surasak PhuphanichJohn S Yu
Nov 8, 2012·Clinical & Developmental Immunology·Sadhak SenguptaPrakash Sampath
Jan 8, 2013·World Journal of Clinical Oncology·Ricardo Diez ValleMaurizio Bendandi
Feb 12, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicholas F MarkoRaymond E Sawaya
Feb 21, 2014·The New England Journal of Medicine·Mark R GilbertMinesh P Mehta
Feb 21, 2014·The New England Journal of Medicine·Olivier L ChinotTimothy Cloughesy
Mar 29, 2014·The Journal of Clinical Investigation·Alena GrosSteven A Rosenberg
Nov 8, 2015·The Lancet Oncology·Hideho OkadaDavid A Reardon

❮ Previous
Next ❯

Citations

Mar 20, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M E Rodríguez-RuizI Melero
Sep 27, 2018·Neurologia Medico-chirurgica·Shabierjiang JiapaerMitsutoshi Nakada
Jun 1, 2020·Journal for Immunotherapy of Cancer·John P LynesEdjah K Nduom
Aug 25, 2019·Molecular Cancer·Miao PengZhaoyang Zeng
Oct 13, 2018·Current Treatment Options in Oncology·Lan B Hoang-Minh, Duane A Mitchell
Feb 6, 2019·Frontiers in Immunology·Thiago A PatenteJosé A M Barbuto
Jan 30, 2019·Frontiers in Immunology·Tahir B DarStephen L Shiao
Aug 9, 2020·Nature Reviews. Drug Discovery·Alexandre HarariLana E Kandalaft
Apr 13, 2018·Nature Reviews. Clinical Oncology·Michael LimMichael Weller
Mar 31, 2020·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·P D Delgado-LópezS Tejada
Mar 25, 2020·Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko·I V ChekhoninO I Gurina
Jan 9, 2019·Frontiers in Immunology·Qianquan MaRong-Fu Wang
Nov 1, 2017·Human Vaccines & Immunotherapeutics·Ziren KongWenbin Ma
Oct 28, 2019·Oncoimmunology·Jenny SprootenAbhishek D Garg
Nov 13, 2020·Frontiers in Immunology·Joshua R D PearsonStephanie E B McArdle
Nov 17, 2020·Frontiers in Immunology·Xianhui KangWujun Geng
Dec 31, 2020·Cancers·Stefaan W Van GoolWilfried Stuecker
Feb 12, 2020·Cancer Letters·Shengchao XuZhixiong Liu
Mar 27, 2021·Expert Review of Vaccines·Xiaoling XuYun Fan
Mar 27, 2021·Frontiers in Immunology·Boyuan HuangHongbo Zhang
May 28, 2021·Frontiers in Oncology·Stephen C FredericoMasaki Terabe
Jul 16, 2020·Current Drug Metabolism·Elmira MohtashamiAmir R Afshari
Jul 23, 2021·Journal of Cancer Research and Clinical Oncology·Jiaxing SunQiang Li

❮ Previous
Next ❯

Methods Mentioned

BETA
Surgical
total resection
leukapheresis
FCS
enzyme-linked immunosorbent assay
ELISA
biopsy
flow cytometry

Clinical Trials Mentioned

NCT01006044

Software Mentioned

GraphPad Prism
iRANO
Flow Jo

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.